Interprofessional Pharmacogenomics (IPGx) Registry and Repository
RecruitingObservational study
The Texas Interprofessional Pharmacogenomics Registry and Repository
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or * Individuals taking blood pressure or depression medications, even if less than five medications. * Ability to understand and give consent. * Able to consent to donate blood and/or urine samples and buccal swabs. * Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions. * Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community. * All genders. * Any age over 18 years. Exclusion Criteria: * Individuals admitted to hospice. * Declines to participate or interact with staff/share their medical status. * A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning., * Individuals who are unable or unwilling to provide consent. * Unable to verbally communicate and comprehend English language
About the study
This program collects genetic and health information to help doctors choose the right medications for patients.
Sponsor: Texas A&M University · Participants: 3,000 · Started: 2025-11
Contact the study team
- Kenneth S Ramos, MD, PhD · Phone: (713) 677-7440
Official record on ClinicalTrials.gov — NCT06726590
Locations in the U.S.
| Texas | Texas A&M Family Care, Bryan |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.